CoVaccine HT™ Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization

The current COVID-19 pandemic has claimed hundreds of thousands of lives and its causative agent, SARS-CoV-2, has infected millions, globally. The highly contagious nature of this respiratory virus has spurred massive global efforts to develop vaccines at record speeds. In addition to enhanced immun...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 11; p. 599587
Main Authors Haun, Brien K., Lai, Chih-Yun, Williams, Caitlin A., Wong, Teri Ann S., Lieberman, Michael M., Pessaint, Laurent, Andersen, Hanne, Lehrer, Axel T.
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 30.10.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The current COVID-19 pandemic has claimed hundreds of thousands of lives and its causative agent, SARS-CoV-2, has infected millions, globally. The highly contagious nature of this respiratory virus has spurred massive global efforts to develop vaccines at record speeds. In addition to enhanced immunogen delivery, adjuvants may greatly impact protective efficacy of a SARS-CoV-2 vaccine. To investigate adjuvant suitability, we formulated protein subunit vaccines consisting of the recombinant S1 domain of SARS-CoV-2 Spike protein alone or in combination with either CoVaccine HT™ or Alhydrogel. CoVaccine HT™ induced high titres of antigen-binding IgG after a single dose, facilitated affinity maturation and class switching to a greater extent than Alhydrogel and elicited potent cell-mediated immunity as well as virus neutralizing antibody titres. Data presented here suggests that adjuvantation with CoVaccine HT™ can rapidly induce a comprehensive and protective immune response to SARS-CoV-2.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Suh-Chin Wu, National Tsing Hua University, Taiwan; Srinivasa Reddy Bonam, Institut National de la Santé et de la Recherche Médicale (INSERM), France
Edited by: Anke Huckriede, University Medical Center Groningen, Netherlands
This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2020.599587